Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation

NCT06532279 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT06532279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06532279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation
Lead sponsor
NRG Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
June 23, 2025
Completion date
January 1, 2032
Enrollment
98 (estimated)
Sites
153

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage i hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage ii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, head and neck squamous cell carcinoma, hypopharyngeal squamous cell carcinoma, laryngeal squamous cell carcinoma, nasopharyngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharyngeal squamous cell carcinoma, stage 0 head and neck cutaneous squamous cell carcinoma ajcc v8, stage 0 hypopharyngeal carcinoma ajcc v8, stage 0 nasopharyngeal carcinoma ajcc v8, stage 0 oropharyngeal (p16-negative) carcinoma ajcc v8, stage i head and neck cutaneous squamous cell carcinoma ajcc v8, stage i hypopharyngeal carcinoma ajcc v8, stage i laryngeal cancer ajcc v8, stage i lip and oral cavity cancer ajcc v8, stage i nasopharyngeal carcinoma ajcc v8, stage i oropharyngeal (p16-negative) carcinoma ajcc v8, stage ii head and neck cutaneous squamous cell carcinoma ajcc v8, stage ii hypopharyngeal carcinoma ajcc v8, stage ii laryngeal cancer ajcc v8, stage ii lip and oral cavity cancer ajcc v8, stage ii nasopharyngeal carcinoma ajcc v8, stage ii oropharyngeal (p16-negative) carcinoma ajcc v8, stage iii head and neck cutaneous squamous cell carcinoma ajcc v8, stage iii hypopharyngeal carcinoma ajcc v8, stage iii laryngeal cancer ajcc v8, stage iii lip and oral cavity cancer ajcc v8, stage iii nasopharyngeal carcinoma ajcc v8, stage iii oropharyngeal (p16-negative) carcinoma ajcc v8, stage iva hypopharyngeal carcinoma ajcc v8, stage iva laryngeal cancer ajcc v8, stage iva lip and oral cavity cancer ajcc v8, stage iva nasopharyngeal carcinoma ajcc v8, stage iva oropharyngeal (p16-negative) carcinoma ajcc v8, stage ivb hypopharyngeal carcinoma ajcc v8, stage ivb laryngeal cancer ajcc v8, stage ivb lip and oral cavity cancer ajcc v8, stage ivb oropharyngeal (p16-negative) carcinoma ajcc v8, stomatitis